: Pliant Therapeutics shares rally 75%


Shares of Pliant Therapeutics Inc. PLRX, +2.62% soared about 75% in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibrosis met the primary and secondary endpoints in a Phase 2a clinical trial. Pliant, which is testing four different doses of bexotegrast, said 21 patients received the 320 milligram dose — the highest dose — and will continue to receive treatment for 24 weeks. The final data from the study is expected to come in the second quarter. Pliant’s stock has soared 109.8% over the past year, while the broader S&P 500 SPX, +1.89% is down 9.7%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleFix My Portfolio: I’m about to get $130,000 from a lump-sum pension payout, but I don’t know what to do with it
Next articleSpotify to lay off nearly 600 employees


Please enter your comment!
Please enter your name here